SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
1.550
-0.060 (-3.73%)
At close: Aug 13, 2025, 4:00 PM
1.550
0.00 (0.00%)
After-hours: Aug 13, 2025, 7:02 PM EDT
SLS Employees
SELLAS Life Sciences Group had 15 employees as of December 31, 2024. The number of employees decreased by 1 or -6.25% compared to the previous year.
Employees
15
Change (1Y)
-1
Growth (1Y)
-6.25%
Revenue / Employee
n/a
Profits / Employee
-$1,750,600
Market Cap
162.68M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SLS News
- 6 days ago - SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification - GlobeNewsWire
- 5 weeks ago - SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board - GlobeNewsWire
- 2 months ago - SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts - GlobeNewsWire
- 2 months ago - SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase - GlobeNewsWire
- 3 months ago - SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML - GlobeNewsWire
- 3 months ago - SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference - GlobeNewsWire